RecruitingNot ApplicableNCT07247032

Heart Failure Management for Patient With CIED Remotely Monitored

Prospective Real World Heart Failure Management for Patient With CIED Remotely Monitored


Sponsor

Implicity

Enrollment

1,132 participants

Start Date

Dec 19, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This randomized, controlled, open-label, parallel, multicenter clinical study evaluates the efficacy of SmartSignalHF compared with heart failure (HF) remote monitoring (RM) standard of care in implanted patients with heart failure. The primary objective is to determine whether SmartSignalHF reduces all-cause mortality and HF hospitalizations at 12 months.


Eligibility

Min Age: 18 YearsMax Age: 85 Years

Inclusion Criteria9

  • Patient aged 18-85
  • Patient diagnosed with a New York Heart Association (NYHA) class II or III
  • Patients with left ventricular ejection fraction ≼ 40 %
  • Patient implanted with an ICD or CRT-D (BiV and/or LBBA pacing) since at least 30 days and compatible with SignalHF (Biotronik, Boston Scientific and Medtronic)
  • Non-activation of others HF multisensor algorithms
  • Patient remote monitored on Implicity CIED platform
  • Patient with a documented diagnosis of heart failure, eligible to reimbursement in France or Germany for HF remote monitoring
  • Patient is willing to be remotely monitored for heart failure
  • HF treated according to European Society of Cardiology (ESC) guidelines

Exclusion Criteria7

  • Patients undergoing or awaiting heart transplant or left ventricular assist device (LVAD) procedures
  • Patients with a life expectancy of less than 12 months
  • Patients enrolled in concurrent clinical studies
  • Patients with a history of non-compliance with medical care or inability to comply with the study protocol
  • Patients already receiving remote monitoring for heart failure
  • Pregnant or breastfeeding women
  • Subjects under legal protection

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICESmartSignalHF

SmartSignalHF; a solution aiming to predict episodes of cardiac decompensation in patients implanted with an ICD or CRT-D

DEVICEHF RM standard of care

HF RM standard of care defined in the country (France or Germany)


Locations(1)

Implicity

Paris, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07247032


Related Trials